Study wrapper · #886
Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison.
Mantovani A, Targher G Diabetes, obesity & metabolism. 2026.
DOI: 10.1111/dom.71110PubMed: 42454420
Editor's note
This is an indirect, cross-trial comparison of semaglutide and resmetirom for MASH with fibrosis, not a head-to-head trial. Indirect comparisons carry substantial methodological caveats and cannot establish superiority. Semaglutide is a genuine subject, so it carries moderate signal, but conclusions should be read cautiously given no abstract detail and the exploratory design.
Plain-language abstract
An exploratory indirect comparison weighed semaglutide against resmetirom in patients with metabolic dysfunction-associated steatohepatitis and fibrosis.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026